Clinical Trials Browser

Interventional × Glioblastoma × Topotecan × Clear all

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00014443 2023-01-09

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Phase 2 Terminated

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01004874 2022-04-13

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

Phase 2 Completed

80 enrolled 11 charts

Glioblastoma, Glioma, Gliosarcoma

NCT00610571 2013-10-25

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00541138 2011-09-21

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Neoplasm Metastasis, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma